Allosteric EGFR inhibitors and methods of use thereof

Novel small molecule EGFR inhibitors targeting mutant EGFR offer an alternative to existing TKIs, effectively addressing the limitations of current therapies by inhibiting mutant EGFR with enhanced specificity and potency.

JP2025092596APending Publication Date: 2025-06-19DANA FARBER CANCER INSTITUTE INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2025054050
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-05-27
Filing Date
2025-03-27
Publication Date
2025-06-19

Smart Images

  • Figure 2025092596000001
    Figure 2025092596000001
  • Figure 2025092596000002
    Figure 2025092596000002
  • Figure 2025092596000003
    Figure 2025092596000003
Patent Text Reader

Abstract

To provide potent small molecule epidermal growth factor receptor (EGFR) inhibitors with alternative mechanisms of action targeting mutant EGFR.SOLUTION: The invention relates to: compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Isoindolin-1-one derivatives, methods for preparing the same, and pharmaceutical compositions containing the same as active ingredients for preventing or treating cancer - Patents.com

    JP2021534163A

  • Nitrogen heterocycle biaryls for osteoporosis and other diseases

    WO2007001249A1